Send to

Choose Destination
See comment in PubMed Commons below
Indian Pediatr. 2013 Feb;50(2):237-9.

Thalidomide for systemic onset juvenile idiopathic arthritis.

Author information

Department of Pediatrics, Jaslok Hospital and Research Centre, Mumbai, India.


Systemic onset juvenile idiopathic arthritis (SOJIA) is the most common autoimmune auto inflammatory disease in childhood. A sizeable number of these patients run a recalcitrant disease course, resistant to the conventional line of management, ultimately resulting in permanent disability from joint destruction, local growth deformities or iatrogenic side effects. The new biological agents although very effective, are beyond the affordability of most in our country. Thalidomide, a cheaper option has been shown to be very effective in the disease control of patients with SOJIA. We report three Indian children with a chronic refractory course of SOJIA, all of whom had failed conventional line of treatment but improved with thalidomide.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Indian Pediatrics
    Loading ...
    Support Center